Long-term clinical and endoscopic efficacy of vedolizumab and therapeutic persistence in patients with ulcerative colitis in China: a multicenter observational study.
{"title":"Long-term clinical and endoscopic efficacy of vedolizumab and therapeutic persistence in patients with ulcerative colitis in China: a multicenter observational study.","authors":"Zhaopeng Huang, Lingya Yao, Yun Qiu, Kang Chao, Qing Li, Lang Lin, Jing Liu, Ren Mao, Qian Cao, Minhu Chen, Xiang Gao","doi":"10.5217/ir.2025.00049","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>Limited data are available on the long-term efficacy of vedolizumab (VDZ) in Asian patients with ulcerative colitis (UC), particularly regarding endoscopic outcomes.</p><p><strong>Methods: </strong>In this multicenter, retrospective, real-world study, UC patients treated with VDZ were evaluated for steroid-free remission, endoscopic remission (Mayo endoscopic score ≤ 1), and mucosal healing (Mayo endoscopic score = 0) at weeks 52, 104, and 156. Treatment persistence was analyzed using Kaplan-Meier curves.</p><p><strong>Results: </strong>Among 239 patients, steroid-free remission was achieved in 59.4%, 52.9%, and 40.3% at weeks 52, 104, and 156, respectively. Endoscopic remission and mucosal healing rates were 53.3% and 32.2% at week 52, 39.8% and 27.5% at week 104, and 34.8% and 26.2% at week 156. The probability of treatment persistence was 76.8%, 63.3%, and 56.4% at these time points. Anti-tumor necrosis factor (anti-TNF) exposure was independently associated with a higher risk of failing to achieve long-term VDZ persistence (hazard ratio [HR], 2.754; 95% confidence interval [CI], 1.478-5.135; P= 0.001), whereas achieving early steroid-free remission after induction was an independent protective factor (HR, 0.480; 95% CI, 0.235-0.978; P= 0.043). VDZ-related adverse events occurred in 7.1% of patients, with no serious events reported.</p><p><strong>Conclusions: </strong>VDZ demonstrated long-term clinical and endoscopic efficacy with a high safety profile in Chinese UC patients. Notably, anti-TNF-naive patients with early steroid-free remission were more likely to maintain long-term treatment persistence.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intestinal Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5217/ir.2025.00049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aims: Limited data are available on the long-term efficacy of vedolizumab (VDZ) in Asian patients with ulcerative colitis (UC), particularly regarding endoscopic outcomes.
Methods: In this multicenter, retrospective, real-world study, UC patients treated with VDZ were evaluated for steroid-free remission, endoscopic remission (Mayo endoscopic score ≤ 1), and mucosal healing (Mayo endoscopic score = 0) at weeks 52, 104, and 156. Treatment persistence was analyzed using Kaplan-Meier curves.
Results: Among 239 patients, steroid-free remission was achieved in 59.4%, 52.9%, and 40.3% at weeks 52, 104, and 156, respectively. Endoscopic remission and mucosal healing rates were 53.3% and 32.2% at week 52, 39.8% and 27.5% at week 104, and 34.8% and 26.2% at week 156. The probability of treatment persistence was 76.8%, 63.3%, and 56.4% at these time points. Anti-tumor necrosis factor (anti-TNF) exposure was independently associated with a higher risk of failing to achieve long-term VDZ persistence (hazard ratio [HR], 2.754; 95% confidence interval [CI], 1.478-5.135; P= 0.001), whereas achieving early steroid-free remission after induction was an independent protective factor (HR, 0.480; 95% CI, 0.235-0.978; P= 0.043). VDZ-related adverse events occurred in 7.1% of patients, with no serious events reported.
Conclusions: VDZ demonstrated long-term clinical and endoscopic efficacy with a high safety profile in Chinese UC patients. Notably, anti-TNF-naive patients with early steroid-free remission were more likely to maintain long-term treatment persistence.
期刊介绍：
Intestinal Research (Intest Res) is the joint official publication of the Asian Organization for Crohn''s and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn''s Foundation (India) (CCF, india). The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance. As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines. The Journal also seeks to propagate and exchange useful innovations, both in ideas and in practice, within the research community. As a mode of scholarly communication, it encourages scientific investigation through the rigorous peer-review system and constitutes a qualified and continual platform for sharing studies of researchers and practitioners. Specifically, the Journal presents up-to-date coverage of medical researches on the physiology, epidemiology, pathophysiology, clinical presentations, and therapeutic interventions of the intestinal diseases. General topics of interest include inflammatory bowel disease, colon and small intestine cancer or polyp, endoscopy, irritable bowel syndrome and other motility disorders, infectious enterocolitis, intestinal tuberculosis, and so forth. The Journal publishes diverse types of academic materials such as editorials, clinical and basic reviews, original articles, case reports, letters to the editor, brief communications, perspective, statement or commentary, and images that are useful to clinicians and researchers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
